Trade Genprex, Inc. - GNPX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.0269 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 0.796 |
| Open* | 0.828 |
| 1-Year Change* | -64.62% |
| Day's Range* | 0.7949 - 0.8526 |
| 52 wk Range | 0.74-2.67 |
| Average Volume (10 days) | 389.42K |
| Average Volume (3 months) | 8.60M |
| Market Cap | 41.01M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 51.97M |
| Revenue | N/A |
| EPS | -0.47 |
| Dividend (Yield %) | N/A |
| Beta | -0.37 |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 22, 2023 | 0.7960 | -0.0021 | -0.26% | 0.7981 | 0.8149 | 0.7775 |
| Mar 21, 2023 | 0.7603 | 0.0151 | 2.03% | 0.7452 | 0.7772 | 0.7283 |
| Mar 20, 2023 | 0.7274 | -0.0656 | -8.27% | 0.7930 | 0.7931 | 0.7210 |
| Mar 17, 2023 | 0.7449 | -0.0700 | -8.59% | 0.8149 | 0.8149 | 0.7283 |
| Mar 16, 2023 | 0.7870 | -0.0179 | -2.22% | 0.8049 | 0.8091 | 0.7558 |
| Mar 15, 2023 | 0.7945 | -0.0751 | -8.64% | 0.8696 | 0.8781 | 0.7677 |
| Mar 14, 2023 | 0.8400 | -0.1078 | -11.37% | 0.9478 | 0.9541 | 0.8400 |
| Mar 13, 2023 | 0.8952 | 0.0272 | 3.13% | 0.8680 | 0.9172 | 0.8505 |
| Mar 10, 2023 | 0.8868 | -0.1109 | -11.12% | 0.9977 | 1.0077 | 0.8779 |
| Mar 9, 2023 | 0.9977 | -0.0299 | -2.91% | 1.0276 | 1.0376 | 0.9937 |
| Mar 8, 2023 | 1.0276 | -0.0699 | -6.37% | 1.0975 | 1.0975 | 1.0077 |
| Mar 7, 2023 | 1.0276 | -0.0699 | -6.37% | 1.0975 | 1.1075 | 1.0176 |
| Mar 6, 2023 | 1.0875 | -0.0200 | -1.81% | 1.1075 | 1.1175 | 1.0875 |
| Mar 3, 2023 | 1.1175 | -0.0299 | -2.61% | 1.1474 | 1.1574 | 1.0875 |
| Mar 2, 2023 | 1.1274 | -0.0100 | -0.88% | 1.1374 | 1.1574 | 1.0576 |
| Mar 1, 2023 | 1.1274 | -0.1197 | -9.60% | 1.2471 | 1.2671 | 1.1174 |
| Feb 28, 2023 | 1.2671 | 0.1597 | 14.42% | 1.1074 | 1.3370 | 1.1074 |
| Feb 27, 2023 | 1.1174 | -0.1098 | -8.95% | 1.2272 | 1.2272 | 1.0975 |
| Feb 24, 2023 | 1.3170 | 0.0000 | 0.00% | 1.3170 | 1.3769 | 1.2970 |
| Feb 23, 2023 | 1.3669 | -0.3992 | -22.60% | 1.7661 | 1.8659 | 1.2871 |
Genprex, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 19.6008 | 17.9616 | 10.6827 | 12.3635 | 3.31235 |
| Selling/General/Admin. Expenses, Total | 10.9705 | 10.6359 | 8.7026 | 11.3862 | 3.01917 |
| Research & Development | 8.60775 | 7.30292 | 1.96701 | 0.97143 | 0.28993 |
| Depreciation / Amortization | 0.02253 | 0.02278 | 0.01307 | 0.00589 | 0.00324 |
| Operating Income | -19.6008 | -17.9616 | -10.6827 | -12.3635 | -3.31235 |
| Net Income Before Taxes | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| Net Income After Taxes | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| Net Income Before Extra. Items | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| Net Income | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| Income Available to Common Excl. Extra. Items | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| Income Available to Common Incl. Extra. Items | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| Dilution Adjustment | |||||
| Diluted Net Income | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| Diluted Weighted Average Shares | 47.0973 | 35.5229 | 16.027 | 13.771 | 13.035 |
| Diluted EPS Excluding Extraordinary Items | -0.41607 | -0.5051 | -0.6648 | -0.89843 | -0.25425 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Diluted Normalized EPS | -0.41607 | -0.5051 | -0.6648 | -0.89843 | -0.25425 |
| Interest Income (Expense), Net Non-Operating | 0.00513 | 0.01881 | 0.02791 | -0.0088 | -0.00181 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 5.72336 | 5.68292 | 3.43893 | 3.98722 | 6.4917 |
| Selling/General/Admin. Expenses, Total | 3.8558 | 2.19563 | 2.00044 | 2.4581 | 4.31631 |
| Research & Development | 1.86084 | 3.48033 | 1.432 | 1.52628 | 2.16914 |
| Depreciation / Amortization | 0.00673 | 0.00696 | 0.00649 | 0.00285 | 0.00624 |
| Operating Income | -5.72336 | -5.68292 | -3.43893 | -3.98722 | -6.4917 |
| Interest Income (Expense), Net Non-Operating | 0.00088 | 0.00099 | 0.00106 | 0.0011 | 0.00198 |
| Net Income Before Taxes | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
| Net Income After Taxes | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
| Net Income Before Extra. Items | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
| Net Income | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
| Income Available to Common Excl. Extra. Items | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
| Income Available to Common Incl. Extra. Items | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
| Diluted Net Income | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
| Diluted Weighted Average Shares | 47.8796 | 47.8353 | 47.6124 | 47.3725 | 45.5461 |
| Diluted EPS Excluding Extraordinary Items | -0.11952 | -0.11878 | -0.07221 | -0.08414 | -0.14249 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.11952 | -0.11878 | -0.07221 | -0.08414 | -0.14249 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Current Assets | 39.1402 | 27.7044 | 2.97664 | 8.84707 | 0.19357 |
| Cash and Short Term Investments | 38.6289 | 27.3197 | 2.00249 | 8.60092 | 0.16125 |
| Cash | 38.6289 | 27.3197 | 2.00249 | 8.60092 | 0.16125 |
| Prepaid Expenses | 0.51135 | 0.38455 | 0.17172 | 0.23685 | 0.02348 |
| Total Assets | 42.8623 | 31.3672 | 3.53423 | 9.26896 | 1.25954 |
| Property/Plant/Equipment, Total - Net | 0.04861 | 0.03944 | 0.04465 | 0.02435 | 0.0078 |
| Intangibles, Net | 3.66476 | 3.61267 | 0.4912 | 0.37945 | 0.29857 |
| Other Long Term Assets, Total | 0.00869 | 0.01074 | 0.02173 | 0.01809 | 0.75959 |
| Total Current Liabilities | 1.5853 | 0.45072 | 0.51068 | 0.38782 | 0.83096 |
| Accounts Payable | 0.9732 | 0.19297 | 0.43626 | 0.29507 | 0.62907 |
| Notes Payable/Short Term Debt | 0 | 0 | 0.07443 | 0.09275 | 0.20189 |
| Total Liabilities | 1.5853 | 0.45072 | 0.51068 | 0.38782 | 0.83096 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 41.277 | 30.9165 | 3.02355 | 8.88114 | 0.42857 |
| Preferred Stock - Non Redeemable, Net | |||||
| Common Stock | 0.04787 | 0.04312 | 0.01926 | 0.01524 | 0.01172 |
| Additional Paid-In Capital | 119.247 | 89.2956 | 43.4837 | 38.6906 | 17.8692 |
| Retained Earnings (Accumulated Deficit) | -78.0179 | -58.4222 | -40.4795 | -29.8247 | -17.4524 |
| Total Liabilities & Shareholders’ Equity | 42.8623 | 31.3672 | 3.53423 | 9.26896 | 1.25954 |
| Total Common Shares Outstanding | 47.8747 | 43.1177 | 19.2638 | 15.2392 | 13.035 |
| Total Receivables, Net | 0 | 0.00013 | 0.00066 | 0.0093 | 0.00884 |
| Accounts Receivable - Trade, Net | 0 | 0.00013 | 0.00066 | 0.0093 | 0.00884 |
| Total Inventory | 0.80178 | ||||
| Other Current Liabilities, Total | 0.6121 | 0.25776 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 35.7031 | 39.1402 | 45.6447 | 48.0615 | 50.3777 |
| Cash and Short Term Investments | 34.5553 | 38.6289 | 42.0205 | 44.2435 | 47.0687 |
| Cash | 34.5553 | 38.6289 | 42.0205 | 44.2435 | 47.0687 |
| Total Receivables, Net | 0.03217 | 0 | 0.00013 | 0.00013 | 0.00013 |
| Accounts Receivable - Trade, Net | 0.03217 | 0 | 0.00013 | 0.00013 | 0.00013 |
| Total Inventory | 2.87505 | 3.06236 | 3.1079 | ||
| Prepaid Expenses | 1.1156 | 0.51135 | 0.74903 | 0.7556 | 0.201 |
| Total Assets | 39.4094 | 42.8623 | 46.3272 | 48.7314 | 51.0365 |
| Property/Plant/Equipment, Total - Net | 0.04188 | 0.04861 | 0.04434 | 0.03949 | 0.0373 |
| Intangibles, Net | 3.65444 | 3.66476 | 0.62736 | 0.61967 | 0.6107 |
| Other Long Term Assets, Total | 0.01 | 0.00869 | 0.01074 | 0.01074 | 0.01074 |
| Total Current Liabilities | 2.38482 | 1.5853 | 1.16189 | 1.04722 | 0.61363 |
| Accounts Payable | 1.25298 | 0.9732 | 0.59194 | 0.36979 | 0.33897 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.13184 | 0.6121 | 0.56995 | 0.67743 | 0.27466 |
| Total Liabilities | 2.38482 | 1.5853 | 1.16189 | 1.04722 | 0.61363 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 37.0246 | 41.277 | 45.1653 | 47.6842 | 50.4229 |
| Common Stock | 0.04788 | 0.04787 | 0.0478 | 0.04752 | 0.04732 |
| Additional Paid-In Capital | 120.717 | 119.247 | 117.453 | 116.535 | 115.287 |
| Retained Earnings (Accumulated Deficit) | -83.7403 | -78.0179 | -72.3359 | -68.8981 | -64.9119 |
| Total Liabilities & Shareholders’ Equity | 39.4094 | 42.8623 | 46.3272 | 48.7314 | 51.0365 |
| Total Common Shares Outstanding | 47.8797 | 47.8747 | 47.8036 | 47.5229 | 47.3148 |
| Other Equity, Total | 0 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| Cash From Operating Activities | -14.2849 | -13.9351 | -6.91872 | -6.84653 | -2.17159 |
| Cash From Operating Activities | 0.02253 | 0.02278 | 0.01307 | 0.00589 | 0.00324 |
| Non-Cash Items | 4.27821 | 4.24619 | 3.52998 | 5.43538 | 1.32389 |
| Changes in Working Capital | 1.00995 | -0.26128 | 0.19299 | 0.08454 | -0.18457 |
| Cash From Investing Activities | -0.0838 | -2.33725 | -0.9469 | -0.10332 | -0.06342 |
| Capital Expenditures | -0.07244 | -0.12799 | -0.14512 | -0.10332 | -0.06342 |
| Cash From Financing Activities | 25.6779 | 41.5895 | 1.26719 | 15.3895 | 0.79397 |
| Issuance (Retirement) of Stock, Net | 25.6779 | 41.5895 | 1.26719 | 15.3895 | 0.79397 |
| Net Change in Cash | 11.3092 | 25.3172 | -6.59843 | 8.43967 | -1.44104 |
| Other Investing Cash Flow Items, Total | -0.01136 | -2.20926 | -0.80178 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -5.72248 | -19.5956 | -13.9137 | -10.4758 | -6.48971 |
| Cash From Operating Activities | -4.08386 | -14.2849 | -11.0668 | -8.43209 | -5.46528 |
| Cash From Operating Activities | 0.00673 | 0.02253 | 0.01558 | 0.00909 | 0.00624 |
| Non-Cash Items | 1.47011 | 4.27821 | 2.48457 | 1.8092 | 0.67174 |
| Cash Taxes Paid | 0 | 0 | |||
| Cash Interest Paid | 0 | 0 | |||
| Changes in Working Capital | 0.16179 | 1.00995 | 0.34669 | 0.22545 | 0.34645 |
| Cash From Investing Activities | 0.01032 | -0.0838 | 0.08978 | -0.07851 | -0.11003 |
| Capital Expenditures | -0.00184 | -0.07244 | -0.04622 | -0.02719 | -0.10077 |
| Other Investing Cash Flow Items, Total | 0.01216 | -0.01136 | 0.136 | -0.05132 | -0.00926 |
| Cash From Financing Activities | 0 | 25.6779 | 25.6779 | 25.4344 | 25.3243 |
| Issuance (Retirement) of Stock, Net | 0 | 25.6779 | 25.6779 | 25.4344 | 25.3243 |
| Net Change in Cash | -4.07354 | 11.3092 | 14.7008 | 16.9238 | 19.749 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.5144 | 1826600 | 1043 | 2022-12-31 | LOW |
| Varner (John Rodney) | Individual Investor | 2.2348 | 1161535 | 625000 | 2023-02-18 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.069 | 555623 | 2408 | 2022-12-31 | LOW |
| Confer (Ryan M.) | Individual Investor | 0.8379 | 435499 | 245000 | 2023-02-18 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8314 | 432137 | -8520 | 2022-12-31 | LOW |
| Berger (Mark Stanley) | Individual Investor | 0.4714 | 245000 | 245000 | 2023-02-18 | |
| Vaczy (Catherine M) | Individual Investor | 0.4714 | 245000 | 245000 | 2023-02-18 | |
| Kumar (Hermant) | Individual Investor | 0.3848 | 200000 | 200000 | 2023-02-18 | |
| UBS Financial Services, Inc. | Investment Advisor | 0.3089 | 160546 | -119788 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2496 | 129739 | 0 | 2022-12-31 | LOW |
| Cypress Capital, LLC | Investment Advisor | 0.1924 | 100000 | 0 | 2022-12-31 | MED |
| Verus Capital Partners, LLC | Investment Advisor | 0.1703 | 88500 | -2000 | 2022-12-31 | MED |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1663 | 86430 | 11029 | 2022-12-31 | LOW |
| Group One Trading, L.P. | Research Firm | 0.1161 | 60354 | -79668 | 2022-12-31 | HIGH |
| Silvercrest Asset Management Group LLC | Investment Advisor/Hedge Fund | 0.1077 | 56000 | 0 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.1056 | 54900 | -18656 | 2022-12-31 | HIGH |
| IHT Wealth Management, LLC | Investment Advisor | 0.1008 | 52375 | 0 | 2022-12-31 | LOW |
| Staley Capital Advisers, Inc. | Hedge Fund | 0.0962 | 50000 | 0 | 2022-12-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 0.0687 | 35688 | 21508 | 2022-12-31 | HIGH |
| StoneX Group Inc. | Research Firm | 0.0676 | 35150 | 0 | 2022-12-31 | HIGH |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group500K+
Traders
92K+
Active clients monthly
$53M+
Monthly investing volume
$30M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Genprex, Inc. Company profile
About Genprex Inc
Genprex, Inc. is a clinical-stage gene therapy company focused on developing treatments for cancer and diabetes. The Company's lead cancer drug candidate, REQORSA Immunogene therapy drug (also referred to as GPX-001), is being developed to treat non-small cell lung cancer (NSCLC). The active agent in REQORSA is a TUSC2 gene expressing plasmid that is encapsulated in a DOTAP cholesterol nanoparticle. TUSC2 is a tumor suppressor gene which has both tumor killing (via apoptosis) and immunomodulatory effects. The Company utilizes its ONCOPREX Nanoparticle Delivery System to deliver the TUSC2 gene expressing plasmid to cancer cells. Its diabetes gene therapy, also referred to as GPX-002, is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Genprex Inc revenues was not reported. Net loss increased 9% to $13.9M. Higher net loss reflects General and administrative increase of 13% to $8.8M (expense), Research and development increase of 3% to $5.1M (expense), Interest Income decrease of 76% to $4K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.39 to -$0.30.
| Industry: | Bio Therapeutic Drugs |
Suite 3.322
1601 Trinity Street, Bldg. B
78712
Income Statement
- Annual
- Quarterly
News
Sweatcoin price prediction: What is Sweatcoin?
Can Sweatcoin run to the front of the crypto pack?
15:19, 23 March 2023
Who owns the most bitcoin?
Want to know who owns the most bitcoin? Learn more about the biggest bitcoin whales.
14:54, 23 March 2023
Ethereum price prediction: Post-Merge ETH recovering
Can ETH continue to regain its losses after the market crash that followed The Merge?
14:26, 23 March 2023
Bitcoin price prediction 2030-2050: What might happen to BTC in the long term?
Bitcoin started 2023 with a rally, but for how long can it last and what’s the long-term outlook?
13:52, 23 March 2023
Solana price prediction: Can SOL rebound?
Can SOL cryptocurrency continue to recover?
12:44, 23 March 2023
China Evergrande offers bond and equity swaps in debt restructuring
Adds proposal detail
15:24, 22 March 2023
Mexico inflation rate brings good news, uncertainty remains -Espinosa
Updates with additional information from interview, context
15:19, 22 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com